Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Non-randomized, Open-label, Fixed-sequence Study to Investigate the Effect of Darolutamide (ODM-201) on the Pharmacokinetics of a Probe Substrate of CYP3A4 and P-gp in Healthy Male Volunteers

Next Previous
X
Search
Trial Profile

A Phase I, Non-randomized, Open-label, Fixed-sequence Study to Investigate the Effect of Darolutamide (ODM-201) on the Pharmacokinetics of a Probe Substrate of CYP3A4 and P-gp in Healthy Male Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Darolutamide (Primary) ; Dabigatran etexilate; Midazolam
  • Indications Male breast cancer; Prostate cancer
  • Focus Pharmacokinetics
  • Sponsors Bayer

    • Most Recent Events

    • 30 Sep 2019 Results assessing drug-drug interaction potential of Darolutamide in invitro and invivo studies published in the European Journal of Drug Metabolism and Pharmacokinetics
    • 16 Feb 2019 Results assessing the drug-drug interactionof darolutamide with cytochrome P450 (CYP) and P-glycoprotein (P-gp) substrates in in-vito and in-vivo studies, presented at the 2019 Genitourinary Cancers Symposium
    • 20 Dec 2017 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top